Response of recurrent BRAFV600E mutated ganglioglioma to Vemurafenib as single agent
Open Access
- 19 December 2014
- journal article
- case report
- Published by Springer Science and Business Media LLC in Journal of Translational Medicine
- Vol. 12 (1), 1-7
- https://doi.org/10.1186/s12967-014-0356-1
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi methodNeuro-Oncology, 2013
- The molecular biology of WHO grade I astrocytomasNeuro-Oncology, 2012
- Randomized Study of Two Chemotherapy Regimens for Treatment of Low-Grade Glioma in Young Children: A Report From the Children's Oncology GroupJournal of Clinical Oncology, 2012
- Interplay among BRAF, p16, p53, and MIB1 in pediatric low-grade gliomasNeuro-Oncology, 2012
- Survival in BRAF V600–Mutant Advanced Melanoma Treated with VemurafenibNew England Journal of Medicine, 2012
- BRAFAlterations in Primary Glial and Glioneuronal Neoplasms of the Central Nervous System With Identification of 2 Novel KIAA1549Journal of Neuropathology and Experimental Neurology, 2012
- Targeted Therapy for BRAFV600E Malignant AstrocytomaClinical Cancer Research, 2011
- RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)Nature, 2011
- Oncogenic FAM131B–BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytomaActa Neuropathologica, 2011
- Duplication of 7q34 in Pediatric Low‐Grade Astrocytomas Detected by High‐Density Single‐Nucleotide Polymorphism‐Based Genotype Arrays Results in a Novel BRAF Fusion GeneBrain Pathology, 2009